Literature DB >> 22467244

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice.

Bo Kong1, Li Wang, John Y L Chiang, Youcai Zhang, Curtis D Klaassen, Grace L Guo.   

Abstract

UNLABELLED: Activation of farnesoid X receptor (Fxr, Nr1h4) is a major mechanism in suppressing bile-acid synthesis by reducing the expression levels of genes encoding key bile-acid synthetic enzymes (e.g., cytochrome P450 [CYP]7A1/Cyp7a1 and CYP8B1/Cyp8b1). FXR-mediated induction of hepatic small heterodimer partner (SHP/Shp, Nr0b2) and intestinal fibroblast growth factor 15 (Fgf15; FGF19 in humans) has been shown to be responsible for this suppression. However, the exact contribution of Shp/Fgf15 to this suppression, and the associated cell-signaling pathway, is unclear. By using novel genetically modified mice, the current study showed that the intestinal Fxr/Fgf15 pathway was critical for suppressing both Cyp7a1 and Cyp8b1 gene expression, but the liver Fxr/Shp pathway was important for suppressing Cyp8b1 gene expression and had a minor role in suppressing Cyp7a1 gene expression. Furthermore, in vivo administration of Fgf15 protein to mice led to a strong activation of extracellular signal-related kinase (ERK) and, to a smaller degree, Jun N-terminal kinase (JNK) in the liver. In addition, deficiency of either the ERK or JNK pathway in mouse livers reduced the basal, but not the Fgf15-mediated, suppression of Cyp7a1 and Cyp8b1 gene expression. However, deficiency of both ERK and JNK pathways prevented Fgf15-mediated suppression of Cyp7a1 and Cyp8b1 gene expression.
CONCLUSION: The current study clearly elucidates the underlying molecular mechanism of hepatic versus intestinal Fxr in regulating the expression of genes critical for bile-acid synthesis and hydrophobicity in the liver.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467244      PMCID: PMC3390456          DOI: 10.1002/hep.25740

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

Review 1.  Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms.

Authors:  John Y L Chiang
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

2.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

Authors:  W Xie; A Radominska-Pandya; Y Shi; C M Simon; M C Nelson; E S Ong; D J Waxman; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.

Authors:  Salvatore Modica; Michele Petruzzelli; Elena Bellafante; Stefania Murzilli; Lorena Salvatore; Nicola Celli; Giuseppe Di Tullio; Giuseppe Palasciano; Tarek Moustafa; Emina Halilbasic; Michael Trauner; Antonio Moschetta
Journal:  Gastroenterology       Date:  2011-11-02       Impact factor: 22.682

4.  Vitamin D receptor as an intestinal bile acid sensor.

Authors:  Makoto Makishima; Timothy T Lu; Wen Xie; G Kerr Whitfield; Hideharu Domoto; Ronald M Evans; Mark R Haussler; David J Mangelsdorf
Journal:  Science       Date:  2002-05-17       Impact factor: 47.728

5.  Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

Authors:  C J Sinal; M Tohkin; M Miyata; J M Ward; G Lambert; F J Gonzalez
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

6.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.

Authors:  T T Lu; M Makishima; J J Repa; K Schoonjans; T A Kerr; J Auwerx; D J Mangelsdorf
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

7.  Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction.

Authors:  Tracy J Wright; Raj Ladher; John McWhirter; Cornelis Murre; Gary C Schoenwolf; Suzanne L Mansour
Journal:  Dev Biol       Date:  2004-05-01       Impact factor: 3.582

8.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis.

Authors:  Jason A Holt; Guizhen Luo; Andrew N Billin; John Bisi; Y Yvette McNeill; Karen F Kozarsky; Mary Donahee; Da Yuan Wang; Traci A Mansfield; Steven A Kliewer; Bryan Goodwin; Stacey A Jones
Journal:  Genes Dev       Date:  2003-06-18       Impact factor: 11.361

9.  A G protein-coupled receptor responsive to bile acids.

Authors:  Yuji Kawamata; Ryo Fujii; Masaki Hosoya; Masataka Harada; Hiromi Yoshida; Masanori Miwa; Shoji Fukusumi; Yugo Habata; Takashi Itoh; Yasushi Shintani; Shuji Hinuma; Yukio Fujisawa; Masahiko Fujino
Journal:  J Biol Chem       Date:  2003-01-10       Impact factor: 5.157

10.  Redundant pathways for negative feedback regulation of bile acid production.

Authors:  Li Wang; Yoon-Kwang Lee; Donnie Bundman; Yunqing Han; Sundararajah Thevananther; Chang Soo Kim; Steven S Chua; Ping Wei; Richard A Heyman; Michael Karin; David D Moore
Journal:  Dev Cell       Date:  2002-06       Impact factor: 12.270

View more
  158 in total

1.  Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals.

Authors:  Olga Renner; Simone Harsch; Silke Matysik; Dieter Lütjohann; Gerd Schmitz; Eduard F Stange
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

Review 2.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

3.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.

Authors:  Lulu Sun; Cen Xie; Guang Wang; Yue Wu; Qing Wu; Xuemei Wang; Jia Liu; Yangyang Deng; Jialin Xia; Bo Chen; Songyang Zhang; Chuyu Yun; Guan Lian; Xiujuan Zhang; Heng Zhang; William H Bisson; Jingmin Shi; Xiaoxia Gao; Pupu Ge; Cuihua Liu; Kristopher W Krausz; Robert G Nichols; Jingwei Cai; Bipin Rimal; Andrew D Patterson; Xian Wang; Frank J Gonzalez; Changtao Jiang
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440

Review 4.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

5.  FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice.

Authors:  Min Zhang; Bo Kong; Mingxing Huang; Ruixuan Wan; Laura E Armstrong; Justin D Schumacher; Daniel Rizzolo; Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Dig Liver Dis       Date:  2018-04-23       Impact factor: 4.088

6.  Chronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1.

Authors:  Weibin Wu; Qing Wu; Xinmei Liu
Journal:  Cell Cycle       Date:  2019-06-25       Impact factor: 4.534

7.  β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.

Authors:  Michael D Thompson; Akshata Moghe; Pamela Cornuet; Rebecca Marino; Jianmin Tian; Pengcheng Wang; Xiaochao Ma; Marc Abrams; Joseph Locker; Satdarshan P Monga; Kari Nejak-Bowen
Journal:  Hepatology       Date:  2018-01-26       Impact factor: 17.425

8.  Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice.

Authors:  Yang Xu; Fei Li; Munaf Zalzala; Jiesi Xu; Frank J Gonzalez; Luciano Adorini; Yoon-Kwang Lee; Liya Yin; Yanqiao Zhang
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

Review 9.  Bile acids are nutrient signaling hormones.

Authors:  Huiping Zhou; Phillip B Hylemon
Journal:  Steroids       Date:  2014-05-10       Impact factor: 2.668

10.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.